Rett syndrome (RTT) is an X-linked neurological disorder caused by mutations in the methyl-CpG-binding protein 2 (MeCP2) gene. The majority of RTT missense mutations disrupt the interaction of the MeCP2 with DNA or the nuclear receptor corepressor (NCoR)/silencing mediator of retinoic acid and thyroid receptors (SMRT) corepressor complex. Here, we show that the "NCoR/SMRT interaction domain" (NID) of MeCP2 directly contacts transducin beta-like 1 (TBL1) and TBL1 related (TBLR1), two paralogs that are core components of NCoR/SMRT. We determine the cocrystal structure of the MeCP2 NID in complex with the WD40 domain of TBLR1 and confirm by in vitro and ex vivo assays that mutation of interacting residues of TBLR1 and TBL1 disrupts binding to MeCP2. Strikingly, the four MeCP2-NID residues mutated in RTT are those residues that make the most extensive contacts with TBLR1. Moreover, missense mutations in the gene for TBLR1 that are associated with intellectual disability also prevent MeCP2 binding. Our study therefore reveals the molecular basis of an interaction that is crucial for optimal brain function.
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MeCP2 | NCoR/SMRT | Rett syndrome | TBL proteins | intellectual disability T he methyl-CpG-binding protein 2 (MeCP2) is a chromatinassociated factor that is highly expressed in the brain (1, 2) . Loss-of-function mutations in MeCP2 lead to the severe pediatric neurological disorder, Rett syndrome (RTT) (3) , which affects around one in 10,000 girls. In addition, extra copies of the gene cause MeCP2 duplication syndrome (4, 5) , a distinct intellectual disability disorder that predominantly affects males (6) . The importance of MeCP2 for brain function has prompted investigation of its molecular function. The protein was identified because of its ability to bind DNA via its methyl-CpG-binding domain (MBD) (1, 7) and many residues mutated in RTT disrupt this interaction (8) (9) (10) (11) . In addition to DNA, numerous protein partners of MeCP2 have been reported (11) . Of these protein partners, only the interactions with the nuclear receptor corepressor (NCoR) and its close relative silencing mediator of retinoic acid and thyroid receptors (SMRT) (12) (13) (14) are known to be disrupted by RTT missense mutations (13) . Accordingly, Rett missense mutations outside the MBD are found clustered within the so-called "NCoR/SMRT interaction domain" (NID) (13) (Fig. 1A and Fig. S1A ). One NID mutation, R306C, causes a severe RTT-like phenotype in mice (13, 15, 16) . Moreover, mouse models of MeCP2 duplication syndrome suggest that both the MBD and the NID must be intact for this adverse molecular pathology to develop (16, 17) .
These findings indicate that the NID mediates an essential function of MeCP2. This function may be recruitment of the NCoR/ SMRT corepressor complexes to chromatin. Alternatively, the NID may perform other essential roles, such as DNA binding, whose loss leads to RTT (16) . In an attempt to distinguish among these possibilities, we investigated the molecular basis of the interaction between MeCP2 and NCoR/SMRT. The latter are ∼1.2-MDa multisubunit complexes that include NCoR1 (and/or SMRT), HDAC3, GPS2, and transducin beta-like 1 (TBL1) [and/or its paralog TBL 1 related (TBLR1)] (18-21). We show here that the TBL1 and TBLR1 subunits (89% identical in amino acid sequence in humans; Fig. S1B ) are direct MeCP2-binding partners. The crystal structure of a minimal MeCP2-TBLR1 complex at 2.5 Å resolution reveals that the four MeCP2 NID residues most intimately contacting TBLR1 are the same residues that are mutated in RTT. This finding strongly suggests that sustaining this interaction is the primary function of the NID. Mutations in the TBLR1 WD40 domain that disrupt MeCP2-NID binding in vitro also prevent recruitment of TBL1 to heterochromatic foci in cells. Finally, we show that intellectual disabilityassociated missense mutations in TBLR1 disrupt its interaction with MeCP2, supporting the view that this interaction is critical for brain function.
Results

MeCP2
Interacts with NCoR/SMRT and TBL1 in Cells. Previously, we showed that a MeCP2-derived NID peptide could pull down an NCoR1 fragment spanning residues 197-598 (13) . To define the MeCP2-binding site on the NCoR/SMRT complex, we used a similar strategy with FLAG-tagged NCoR1 fragments expressed in HeLa cells ( Fig. 1 A and B) . Like NCoR1 (residues 197-598), NCoR1 fragments spanning residues 197-490 and 227-490 were bound efficiently by a wild-type NID peptide corresponding to Significance Methyl-CpG-binding protein 2 (MeCP2) links epigenetics, brain function, and neurological disease. Mutations in the MeCP2 protein cause Rett syndrome (RTT), making it imperative to determine its mechanism of action. One domain of MeCP2 targets it to methylated DNA, but little was known about a second essential domain except that it recruits a gene-silencing complex. We determined that transducin beta-like (TBL) subunits of the silencing complex bind MeCP2 and solved the structure of the binary complex. Strikingly, amino acids mutated in RTT are precisely those amino acids that intimately contact the TBL subunits. Furthermore, mutations in TBL proteins that cause intellectual disability block interaction with MeCP2. Our data suggest that the TBL-MeCP2 interaction is essential for brain function.
residues 285-313 (MeCP2 NID; Fig. 1 A and B) . Two further N-terminal truncations showed reduced binding (residues 241-490) or failed to bind (residues 297-490) (Fig. 1B) . None of these constructs bound to a control NID peptide containing the RTT mutation K305R, confirming specificity. We noted that residues 227-297 of NCoR1, which appear to be involved in binding MeCP2, overlap with the NCoR1 region that interacts with TBL1 and TBLR1 (NCoR1 residues 247-256) (22) . This overlap in interaction site suggested that the MeCP2-NCoR1 interaction might be indirect, mediated by interaction of MeCP2 with endogenous TBL1/TBLR1 present in cell lysates. We used a coimmunoprecipitation (co-IP) assay to test whether the ability of FLAG-tagged NCoR1 deletion fragments to bind to endogenous TBLR1 matched their ability to bind MeCP2. Indeed the NCoR1 fragments (residues 241-490 and 297-490) showed reduced and absent binding to TBLR1, respectively (Fig. 1C) . The correlation between pull-down efficiency of NCoR1 fragments by the NID peptide and TBLR1 suggests that the MeCP2-NCoR1 interaction is bridged by TBL1/TBLR1.
MeCP2 Binds Directly to TBL1 and TBLR1. TBLR1 and TBL1 have an N-terminal tetramerization domain, which interacts with NCoR1, linked to a C-terminal WD40 domain (23) (Figs. 1A and 2A) . To determine the minimal fragment of TBL1 that binds MeCP2, we expressed FLAG-tagged, full-length, N-terminal and C-terminal fragments of TBL1 in HeLa cells (Fig. 2 A and B) . Full-length TBL1 and a C-terminal fragment of TBL1 (residues 176-527) were efficiently precipitated by the MeCP2-NID peptide, whereas the N-terminal domain of TBL1 (residues 1-181) was not (Fig.  2B) . None of the deletion mutants bound to a peptide carrying the K305R RTT mutation. Furthermore, shortening of the WD40 domain to disrupt the first or last repeat (FLAG-TBL1 (residues 200-527) or FLAG-TBL1 (residues 176-488) disrupted the interaction with NID peptide (Fig. 2B ). These deletions likely destabilize the WD40 domain, indicating that an intact TBL1 WD40 domain is required to bind MeCP2.
We next asked whether the NID peptide could interact directly with purified recombinant mouse TBL1 and TBLR1 carboxyl-terminal WD40 domains (CTDs; Fig. 2C and Fig. S2A ). TBL1 WD40 domain was efficiently pulled down by wild-type NID but not by RTT mutant peptides or a peptide containing phosphoThr308, a modification known to interfere with NID binding (24) (Fig. 2C) . A MeCP2 peptide up to and including residue 308, corresponding to a hypomorphic mutation (25) with reduced NCoR binding (13) , also showed weakened binding to TBL1 (Fig. 2C) . These results confirm that MeCP2 NID can bind directly to the WD40 domain of TBL1, both in cell extracts and in vitro. Using surface plasmon resonance (SPR), we measured binding constants (K D s) for alternative NID peptides (NID s , residues 285-309; or NID, residues 285-313) with the mouse TBLR1-CTD (residues 134-514) ( Fig. 2D and Fig. S2B ). Wild-type TBLR1-CTD bound MeCP2 NID and MeCP2 NID S with apparent K D s of 9.5 ± 0.5 μM and 12.9 ± 0.8 μM, respectively. Similar binding constants suggest that MeCP2 residues up to and including residue 309 are sufficient for binding. Finally, we find that a minimal 11-mer peptide, spanning residues 298-309 of MeCP2, is sufficient to bind TBLR1 in fluorescence anisotropy assays (Fig. S2C) . Although the binding affinity of the binary interaction is relatively low, binding in vivo might be enhanced by the tetrameric structure of TBL1/TBLR1. TBL1 Chimeras Show Differential Binding to MeCP2. Because progressive deletions that truncate the WD40 β-propeller domain destabilize the fold, we devised a "phylogenetic" strategy to identify residues required for MeCP2 binding. MeCP2 is only found in vertebrates, but TBL1 homologs are present throughout metazoans. By identifying evolutionarily remote TBL1 homologs, we were able to construct chimeric TBL1 proteins that do not bind MeCP2 while retaining the integrity of the WD40 domain. A Drosophila ortholog, Ebi (83% identity to human and mouse) was successfully pulled down by MeCP2-NID peptide, but a sponge ortholog [Amphimedon queenslandica (58% identity to human and mouse)] was not recovered (Fig. S3A ). To map differences between mouse and sponge sequences, approximate quarters of the mouse TBL1 WD40 sequence were replaced with equivalent segments from sponge (Fig. 3A) . Replacing the second quarter of the mouse sequence (TBL1-chimera1) or the first and last quarters (TBL1-chimera3) showed wild-type binding to MeCP2 peptide, whereas replacement of the third quarter (TBL1-chimera2) abolished binding (Fig. 3A) . To refine the map, we generated a series of mouse TBL1 mutants where up to four consecutive residues were altered to equivalent residues in the sponge thirdquarter sequence ( Fig. S3 B and C). Only mutants with substituted residues 362-364 and 405-406 lost binding (Fig. S3C) . Further mapping identified E364G as a single missense mutation in TBL1 that abolishes the MeCP2 interaction ( Fig. 3B ) but, importantly, does not prevent incorporation of TBL1 into the NCoR/SMRT complex (Fig. S3D) . This residue maps to a surface of human TBLR1 (hTBLR1) that is associated with peptide ligand binding in related proteins (26, 27) (Fig. S3E ).
MeCP2 NID Binds the Top Surface of TBLR1 WD40 Domain. To define the intermolecular interaction fully, we determined a cocrystal structure of mouse TBLR1-CTD with MeCP2-NID S peptide. Crystals diffracted to 2.5 Å in space group P1. The structure was solved by molecular replacement using the coordinates of hTBLR1 as a search model (99.5% identity) [Protein Data Bank (PDB) ID code 4LG9 (27) ]. Four molecules of TBLR1-CTD are present in the asymmetrical unit. After initial refinement, Fo-Fc maps showed clear electron density in two copies of TBLR1-CTD into which the NID S peptide was built. The final model showed good stereochemistry (23) ( Table S1 ). Chain A is the best-defined copy of TBLR1-CTD, where residues 155-513 were visible, with the exception of short loops at residues 203-204 and 217-223. Chains C and D lacked peptide and displayed poor electron density. Although the backbone of these chains could be discerned, many loops and side chains could not be modeled. We therefore restrict our discussion to TBLR1 chain A. Only residues 297-307 of the NID S peptide could be modeled with confidence (Fig. S4A) .
The TBLR1 WD40 domain is an eight-bladed β-propeller domain with a central channel (27) (Fig. 4 A and B) . As in other WD40 domains, the C-terminal WD40 blade contains a β-strand from the first WD40 repeat sequence (28) (Fig. 4A) . The NID S peptide binds the top face of the central channel, a common interaction interface (26, 28) . At the deepest point, the peptide is ∼10 Å inside the channel (Fig. 4B) , burying a surface area of 532 Å 2 on TBLR1 (Fig. 4C) . The TBLR1 interaction surface is highly electronegative (Fig. 4D) , enabling recognition of the cluster of basic residues in the NID. Surface conservation calculations using vertebrate TBLR1 sequences show that the top face is conserved, consistent with a role in protein-protein interactions (29) (Fig. 4E) .
Four Key Residues of MeCP2 Interact with TBLR1. Side chains of residues 301-306 of MeCP2 were well resolved, suggesting that this region forms the core of the interaction (Fig. 5 A and B) . The most striking feature of the NID is a tight backbone turn stabilized by R306
MeCP2 via a network of intra-and intermolecular interactions within the complex. This residue forms a salt bridge with E171 TBLR1 and close contacts with the backbone carbonyl groups of T299 MeCP2 and L301 MeCP2 (Fig. 5A ). These interactions and stereochemical constraints imposed by P302
MeCP2 enable the peptide to enter the central channel (Fig.  5A ). P302
MeCP2 is part of a stretch of hydrophobic residues in the N-terminal part of the MeCP2 core interacting region, which also includes V300 MeCP2 , L301 MeCP2 , and I303 MeCP2 . P302
MeCP2 is buried in a hydrophobic pocket created by three aromatic side chains: Y395 TBLR1 , F420 TBLR1 , and Y446 TBLR1 (Fig. 5B) . The hydroxyl group of Y446 TBLR1 provides a peptide backbone contact, forming a hydrogen bond with the main chain carbonyl of V300 MeCP2 (Fig. 5B) . In addition to R306
MeCP2 , the C-terminal portion of the core NID has two further basic residues: K304 MeCP2 and K305 MeCP2 . Both residues have extensive hydrogen-bonding and ionic interactions with TBLR1. K304
MeCP2 and K305 MeCP2 form hydrogen bonds with main-chain and side-chain moieties of N353 TBLR1 , respectively (Fig. 5B) . K305
MeCP2 is further stabilized by hydrogen bonding with D369
TBLR1 and an ionic interaction with E351 TBLR1 , which lies 3.1 Å away (Fig. 5B) . Notably, E351
TBLR1 is equivalent to E364 in TBL1, which proved to be essential for the interaction with MeCP2 based on our earlier phylogenetic mapping (Fig. 3B and Fig. S3E ). This mode of recognition differs from other WD40 domain peptide interactions involving basic motifs, such as recognition of modified arginine and lysine residues in histone tails, where aromatic cages stabilize the positive charges (30, 31) (Fig. S4B) .
RTT Mutations Disrupt Individual MeCP2-TBLR1 Contacts. Of the 25 MeCP2-NID S peptide residues present in the cocrystal structure (Fig. 1A) , only four make extensive interactions with TBLR1. Strikingly, missense substitutions at each of these four residues (P302, K304, K305, and R306) are reported in multiple independent cases of RTT. On the other hand, pathological substitutions at other NID residues are not reported in a database with over 1,000 RTT mutations (32) . The cocrystal structure explains in molecular detail why known RTT mutations in the NID likely prevent association with the NCoR/SMRT corepressor complex.
The most common RTT mutation in this region, R306C MeCP2 , disrupts TBLR1 binding in two ways. First, loss of the arginine side chain would prevent the formation of a salt bridge with E171 TBLR1 (Fig. 5C) . Second, the mutant cysteine side chain is short and lacks the hydrogen-bonding capacity of the arginine guanidinium group, and so would be unable to stabilize the peptide conformation (Fig. 5C ). RTT mutation K304E
MeCP2 is a charge reversal mutation that likely prevents binding of the peptide by electrostatic repulsion (Fig. 5D) . Two further RTT mutations, P302R
MeCP2 and K305R MeCP2 , introduce larger side chains than the side chains present in the wild-type sequence. The arginine side chain of P302R MeCP2 could not be accommodated in the hydrophobic pocket where P302 MeCP2 binds and would likely also disrupt the kinked backbone conformation of the peptide (Fig. 5E ). K305R
MeCP2 is superficially a conservative substitution. Given the precise arrangement of the MeCP2-NID S peptide in the TBLR1 central channel, however, the longer arginine side chain creates a steric clash that would not be accommodated (Fig. 5F ).
TBLR1 Mutants Disrupt Interactions with MeCP2. To assess the importance of the TBLR1 residues that contact MeCP2, we tested a series of TBLR1 site-directed mutants using the SPR assay ( Fig. 6 A and B) . E171A TBLR1 and E171Q TBLR1 assessed the importance of ionic interactions and hydrogen bonds with R306 MeCP2 and showed a greater than fourfold reduction in binding to MeCP2 (Fig. 6B) . These results suggest that the salt bridge with R306 MeCP2 is more important than hydrogen bonding. Similarly, E351A TBLR1 showed weaker binding, whereas E351D
TBLR1 retained wildtype affinity for MeCP2 (K D = 11.4 ± 0.5 μM), indicating the importance of ionic interactions with K305 MeCP2 (Table 1) . D369A TBLR1 , which is also expected to prevent binding to K305 MeCP2 , and D313N TBLR1 , which should affect the electronegative binding surface, both abolished binding to NID peptide (Fig. 6B, Table 1 , and Fig. S5A) . Finally, the Y446F TBLR1 mutation tested the importance of the hydrogen-bond interactions with V300
. The Y446F TBLR1 mutant showed close to wild-type binding, indicating a minor contribution to the interaction. As a control, C214 TBLR1 , a residue distant from the MeCP2-binding site, was mutated to serine, and this mutant bound similar to wild-type TBLR1. Only small variations in the melting temperature of the mutant proteins were observed (deviations of ±3°C from wild-type melting temperature, 62°C) in thermal denaturation assays (Fig. S5B) , indicating that the structural integrity of the proteins is unaffected. These results corroborate the structural data, because implicated residues are indeed required for efficient TBLR1 binding to MeCP2.
TBL1 Mutants Fail to Colocalize with MeCP2. The structural analysis used only the TBLR1-CTD and an NID peptide. To validate these findings in living cells with full-length proteins, we tested for recruitment of TBL1/TBLR1 mutants to heterochromatin by MeCP2. We previously demonstrated that whereas TBL1-mCherry alone accumulates in the cytoplasm of NIH 3T3 cells, it is targeted to densely methylated heterochromatin when coexpressed with EGFP-MeCP2 (13) . The interaction is dependent on the presence of a functional NID and is disrupted by the missense RTT mutation R306C MeCP2 (13) . Because TBLR1-mCherry constructs gave a weak fluorescent signal compared with TBL1-mCherry, we introduced the equivalent mutations into TBL1 (Fig. 6A) . Unlike wild-type TBL1-mCherry, TBL1 point mutants E184A, D326N, E364A, and D382A showed little or no colocalization with MeCP2 at heterochromatic foci (Fig. 6C ). Mutations for which corresponding mutations in TBL1 do not affect TBLR1 binding in vitro, such as Y459F, showed a wild-type colocalization (Fig. 6C) . The correlation between the effect of mutations on protein distribution ex vivo and the effect on binding in vitro suggests that the molecular recognition observed with minimal interacting domains recapitulates the behavior of full-length proteins in cells. Furthermore, all TBL1 mutants were able to coimmunoprecipitate HDAC3 when transfected into cells, further supporting the conclusion that these mutants retain a native fold (Fig. S5C) . (33) ] revealed six missense mutations in TBL1XR1, the gene encoding TBLR1: H441R, H213Q, A311P, D369E, D370Y, and P444R, associated with intellectual disability and developmental delay. An additional missense mutation in TBL1XR1, L282P, was reported to be associated with sporadic autism spectrum disorder (34) . All of these mutations map to the WD40 domain of TBLR1 (Fig. 7A and Fig. S6A ) Five mutations (H213Q, D370Y, H441R, A311P, and L282P) are likely to disturb the entire fold because they map either to the WD40 consensus sequence (26, 28) or to the hydrophobic core of the protein (35) . Two mutations, P444R and D369E, were of more interest, because they map close to the MeCP2-binding site. Introduction of a large, positively charged residue at P444 might destabilize the hydrophobic binding site formed by Y395, F420, and Y446, and thus interfere with MeCP2 binding (Fig. S6A) , whereas the apparently conservative D369E mutation might block interaction with K305 MeCP2 (Fig. S6A ). To test whether these two mutations prevent interaction with MeCP2, we coprecipitated wild-type or mutant FLAG-TBL1-CTD with MeCP2-NID peptide. We included E184A as a nonbinding control. Neither D382E TBL1 (D369E TBLR1 ) nor P457R TBL1 (P444R TBLR1 ) is efficiently pulled down by MeCP2-NID peptide (Fig. 7B) . Furthermore, these two mutants are not recruited to heterochromatic foci by MeCP2 in cells (Fig. 7C) . Both of these mutants are incorporated efficiently into NCoR/SMRT complexes (Fig. S6B ) and show only small effects on thermal stability (Fig. S6C) , indicating that the mutations did not affect the overall structure of the protein. Consistent with the pull-down assay, the D369E mutation substantially reduced binding to the NID peptide, whereas P444R had a milder effect as assessed by SPR (Fig. S6D) . These clinically important mutations in TBL1/TBLR1 therefore interfere with binding to MeCP2 in cells.
Discussion
The clustering of RTT mutations indicates that there are two functionally important regions in MeCP2. Although the role of the methylated DNA-binding domain is well established, the effect of mutations that cluster in the NID was uncharacterized at the molecular level. Previous studies showed that the MeCP2 NID is required for interactions with the NCoR/SMRT complex in cells. Here, we show that the NCoR/SMRT complex subunit TBL1, and its paralog TBLR1, bind MeCP2 directly via a WD40 domain (Fig. 2) . To our knowledge, this location is unique among known NCoR/SMRT recruiters, which consistently interact with the NCoR/SMRT scaffold proteins themselves.
The most striking aspect of the cocrystal structure is that all residues in the MeCP2 NID that are mutated in RTT play a direct role in binding TBLR1. The exact coincidence between the four residues crucial to the MeCP2-TBL1/TBLR1 interaction and the four residues mutated in RTT makes it highly likely that TBL1 and TBLR1 are essential partners of MeCP2. It is notable that over 200 independent cases of the R306C mutation have been reported, whereas mutation of P302 to R, L, or A has been seen 23 times (32) . Missense mutations at K305 and K304 are rarer, having been reported only four and two times, respectively. Importantly, mutations at each of these amino acids are almost certainly causal due to their demonstrated absence in both parents of at least one patient (13, 32). Given the importance of the MeCP2-TBL1/TBLR1 interaction, it might be expected that mutations in TBL1 or TBLR1 would lead to RTT. TBLR1 missense mutations have been reported in cases of developmental delay and sporadic autism spectrum disorder (33, 34) but, so far, not in patients diagnosed with RTT. Intriguingly, at least two of these mutations disrupt the interaction with MeCP2 in pull-down assays and in cells (Fig.  7) . Differences in clinical presentation between MECP2 and TBL mutations might be expected, because the MECP2 gene is X-linked, and therefore X chromosome inactivation in females leads to an interspersion of functionally wild-type and mutant cells. This kind of mosaicism does not apply to the autosomal gene TBL1XR1, where mutations would affect all cells. It may also be relevant that TBL1 and TBLR1 exist in the same multiprotein complex, and so may partially complement each other's function. These considerations may lead to differences between phenotypic and/or clinical consequences of MECP2 and TBL mutations. An additional possibility is that TBL proteins interact with proteins other than MeCP2, and effects of mutations on these interactions could also contribute to neurological phenotypes in humans. Future work is needed to address these possibilities.
The combination of structural, biochemical, and functional insights presented here provides strong evidence that the tripartite interaction between DNA, MeCP2, and TBL1/TBLR1 is crucial for brain function. Our cocrystal structure will inform future therapeutic strategies to combat RTT and other MECP2-related disorders. In particular, we note that small molecules that specifically interfere with the interaction may be useful in treating the severe neurological condition MECP2 duplication syndrome.
Materials and Methods
Co-IP and Pull-Down Assays. Cells transiently transfected with p3xFLAG CMV 10 vectors encoding NCoR1 and TBL1 fragments were Dounce-homogenized in NE10 buffer [20 mM Hepes·NaOH (pH 7.5), 10 mM NaCl, 1 mM MgCl 2 , 0.1% Triton X-100 (vol/vol), protease inhibitors (Roche), 15 mM β-mercaptoethanol] and then treated at 25°C for 5 min with 250 units of benzonase (Sigma) per 10 7 cells. The NaCl concentration was adjusted to 150 mM. After mixing for 20 min, lysates were cleared by centrifugation at 16,000 × g for 20 min. Pull-downs and co-IPs were performed as described previously (13) . Antibodies used were M2 anti-FLAG (Sigma) and anti-mCherry (Chromotek). For Western blots, antibodies used were anti-HDAC3 (sc-11417; Santa Cruz Biotechnology), anti-TBLR1 (A300-408A; Bethyl), M2 anti-FLAG (Sigma), and anti-mCherry (ab167453; Abcam).
Protein Expression and Purification. TBLR1-CTD (residues 134-514) was expressed as an N-terminal 6× His-tagged protein in Sf9 cells infected at a density of 2 × 10 6 cells per milliliter with 1:50 virus/medium using a V2 stock.
After 3 d, infected cells were resuspended in 20 mM Tris·HCl (pH 7.5), 500 mM NaCl, 10 mM imidazole, and 1 mM Pefabloc (Roche) supplemented with a complete EDTA-free protease inhibitor mixture tablet (Roche). Cells were sonicated on ice, and the lysate was cleared by centrifugation at 50,000 × g at 4°C for 45 min. His-tagged protein was batch-purified using Ni 2+ -nitrilotriacetic acid resin, washed twice with 20 mM Tris·HCl (pH 7.5), 500 mM NaCl, and 20 mM imidazole, and eluted with 20 mM Tris·HCl (pH 7.5), 500 mM NaCl, and 500 mM imidazole. Eluted protein was dialyzed overnight at 4°C into 20 mM Tris·HCl (pH 7.5), 200 mM NaCl, and 1 mM DTT, and then separated by size-exclusion chromatography.
Thermal Denaturation Assays. The stability of wild-type and mutant TBLR1 was tested in thermal denaturation assays at a final protein concentration of 2 μM and 5× SYPRO dye. The assay was performed on a Biorad IQ5 ICycler using a range of 20-90°C, increments of 1°C, and a hold time of 30 s. Melting temperatures were obtained from the minimum of the negative first derivative of the fluorescence when plotted against temperature [−d(RFU)/dT vs. T].
Crystallization and Structure Refinement. The TBLR1-CTD-MeCP2 complex was formed by mixing TBLR1 (10 mg/mL) with a peptide corresponding to residues 285-309 of MeCP2 (MeCP2 NID S ; Thermo Fisher) in a protein/peptide ratio of 1:1.2. Crystals were grown by hanging drop vapor diffusion in 100 mM 3-(N-morpholino)propanesulfonic acid (pH 7.5) and 18% PEG 3350 at 18°C. Crystals were cryoprotected by supplementing buffer with 30% glycerol and flash-cooled to 100 K. Diffraction data were collected at beamline I03 at the Diamond Light Source. Data were indexed and integrated with XDS and merged using SCALA (36, 37) . Phases were obtained by molecular replacement in PHASER (38) . Coordinates of hTBLR1 [PDB ID code 4LG9 (27) ] were used as a search model. The structure was built using iterative rebuilding in Coot and refinement with PHENIX using NCS restraints (39, 40) .
SPR Assays. Wild-type and mutant biotin-PEG-PEG-MeCP2 peptides spanning residues 285-313 (MeCP2 NID) and biotin-PEG-PEG-MeCP2 spanning residues 285-309 (MeCP2 NID S ) (Thermo Fisher) were immobilized on SA sensor chips (GE Healthcare). All experiments were performed at 25°C using a BIAcore T200 instrument (GE Healthcare). Binding reactions were carried out in 20 mM Tris·HCl (pH 7.5), 200 mM NaCl, and 1 mM DTT. MeCP2 peptides (20 nM) were injected onto the chip to maximum response unit values of ∼10. Channels for MeCP2-NID, MeCP2-NID S , and MeCP2-NID R306C peptides and a reference channel were used in parallel. TBLR1 (or a TBLR1 mutant), supplemented with 100 U/mL heparin, was injected at 30 μL·min −1 for 30 s at concentrations increasing from 0.625 to 40 μM. Data were analyzed using BIAcore T200 Evaluation software. Binding constants were derived from steady-state analysis.
Colocalization Assays. Indicated mutations were introduced into pEGFP-C3-MeCP2 and pN1-TBL1-mCherry expression vectors, as described previously (13) . NIH 3T3 cells were grown on glass coverslips and transfected using JetPei (Polyplus). After 24 h, the growth medium was changed, and after 48 h, cells were fixed in 4% paraformaldehyde for 15 min. Cells were then washed with PBS and stained with DAPI before being mounted on slides with Prolong Diamond (Life Technologies). Finally, slides were photographed using a Zeiss Airyscan microscope.
